【Can-Fite BioPharma- Product CF101&CF102】Can-Fite Reports 2020 Financial Results & Provides Clinical Development Update

Partner News

26th Mar, 2021– Can-Fite
BioPharma Ltd. today issued a new, which is summarized as follows:

Phase III Psoriasis Study
Continues to Enroll Based on Positive Interim Analysis – In October 2020, the
Independent Data Monitoring Committee for Can-Fite’s Phase III trial of
Piclidenoson in the treatment of moderate-to-severe plaque psoriasis reviewed the
blinded study data and recommended the Company continue to enroll patients. The
majority of costs associated with the Phase III Comfort? study have been
previously paid.

Phase IIb NASH Study
Expected to Commence Q4 2021 – Based on a successfully concluded Phase IIa
NASH/NAFLD study with Namodenoson which met its primary endpoint, Can-Fite is
working closely with top Key Opinion Leaders in liver disease to complete its
study design for a Phase IIb study. Can-Fite expects to commence the study
before the end of 2021.

Pivotal Phase III Liver
Cancer Study Expected to Commence Q4 2021 – Can-Fite has reached agreements
with the U.S. FDA and the European Medicines Agency on the protocol of a
pivotal Phase III study for the treatment of hepatocellular carcinoma (HCC),
the most common form of liver cancer. Should the study meet its efficacy
endpoint and be approved by the FDA and EMA, Namodenoson would become one of
only a few drugs available to treat advanced liver cancer patients.

The original website link: